GenWay Biotech’s New Cardiovascular Blood Test Fulfills Unmet Need to Access Risk of Near Term Heart AttackAdvertorial: Biotech Supplement Monday, February 20, 2012
In the U.S. alone, there are more than 18 million patients with coronary artery disease (CAD). It is the largest cause of death in the U.S. and the world. Each year more than 1 million Americans will suffer a new or recurring heart attack resulting in more than 425,000 deaths, according to the National Institute of Health and Medical News Today.
FirstMark, the diagnostic division of GenWay, recognized the essential need to provide CAD patients a solution to predict the risk of near term heart attack. In collaboration with Arshed Quyyumi (Emory University) and Stephen Epstein (MedStar Health Research Institute), GenWay has developed and introduced a simple blood test that distinguishes the top 5 percent of CAD patients that are at a 5.5 times greater risk of a near term (two to three years) heart attack. The test allows physicians to distinguish CAD patients in urgent need of the most aggressive treatment, therapy and monitoring, bringing hope for earlier intervention that will ultimately save lives.
The test provides for an unmet need in cardiovascular medicine to access the risk of a near term heart attack. According to the National Heart, Lung, and Blood Institute, other tests are primarily used as a diagnostic marker to determine whether a symptomatic
patient is suffering an acute cardiovascular event, or to evaluate risk immediately following a cardiac event.
In addition, chronic or fixed risk factors are best suited to predict long term, rather than near term risk.
Since 1998, GenWay Biotech has provided unparalleled solutions and applications to the health care and research communities. Leading the test’s development and commercialization is Thomas Silberg, President and CEO of GenWay Biotech. Mr. Silberg brings more than 35 years of experience leading pharmaceutical and biotech companies including Hoffmann-La Roche, Ligand Pharmaceuticals, Abraxis Bioscience, and APP Pharmaceuticals. “I believe the demand for this new test is inevitable, and I’m inspired and hopeful about the benefit the test will bring to coronary artery disease patients,” said Mr. Silberg.
FirstMark recently launched the test under the name PREvent at the American Heart Association Scientific Sessions in Orlando, Florida, in November 2011. FirstMark will promote the test’s benefits focusing on cardiologists and primary care physicians.
Submitted by GenWay Biotech
For more information please visit www.firstmarkprevent.com